Affiliation:
1. Department of Clinical medicine, Faculty of Health Sciences, University of Copenhagen, Denmark
2. Copenhagen University Hospital, Herlev and Gentofte, Denmark
Abstract
Abstract
Background
Chemo-radiotherapy with curative intent for anal cancer has high complete remission rates, but acute treatment-related gastrointestinal (GI) toxicity is significant. Toxicity occurs due to irradiation of surrounding normal tissue. Current radiotherapy requires the addition of large planning margins to the radiation field to ensure target coverage regardless of the considerable organ motion in the pelvic region. This increases the irradiated volume and radiation dose to the surrounding normal tissue and thereby toxicity. Online adaptive radiotherapy uses artificial intelligence to adjust the treatment to the anatomy of the day. This allows for the reduction of planning margins, minimizing the irradiated volume and thereby radiation to the surrounding normal tissue.
This study examines if cone beam computed tomography (CBCT)-guided oART with daily automated treatment re-planning can reduce acute gastrointestinal toxicity in patients with anal cancer.
Methods/Design
The study is a prospective, single-arm, phase II trial conducted at Copenhagen University Hospital, Herlev and Gentofte, Denmark. 205 patients with locally advanced anal cancer, referred for chemo-radiotherapy with curative intent, are planned for inclusion. Toxicity and quality of life are reported with Common Terminology Criteria of Adverse Events and patient-reported outcome questionnaires, before, during, and after treatment. The primary endpoint is a reduction in the incidence of acute treatment-related grade ≥2 diarrhea from 36% to 25% after daily online adaptive radiotherapy compared to historical data for standard radiotherapy. Secondary endpoints include all acute and late toxicity, overall survival, and reduction in treatment interruptions.
Results
Accrual began in January 2022 and is expected to finish in January 2026. Primary endpoint results are expected to be available in April 2026.
Discussion
This is the first study utilizing online adaptive radiotherapy to treat anal cancer. We hope to determine whether there is a clinical benefit for the patients, with significant reductions in acute GI toxicity without compromising treatment efficacy.
Trial registration:
ClinicalTrials.gov Identifier: NCT05438836
Danish Ethical Committee: H-21028093
Publisher
Research Square Platform LLC
Reference29 articles.
1. International trends in anal cancer incidence rates;Islami F;Int J Epidemiol,2017
2. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial;James RD;Lancet Oncol,2013
3. RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal;Kachnic LA;Int J Radiation Oncology*Biology*Physics,2013
4. : results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research;Epidermoid anal cancer;Lancet,1996
5. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆);Rao S;Ann Oncol,2021